3Patton JA, Townsend DW, Hutton BF. Hybrid imaging technology: from dreams and vision to clinical devices[J]. Semin Nucl Med, 2009, 39(4):247-263.
4Park SS, Lee KT, Lee KH, et al. Diagnostic usefulness of PET/CT for pancreatic malignancy [J]. Korean J Gastroenterol, 2009, 54(4): 235-242.
5Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinomas [J]. Rozhl Chit, 2010, 89(7):433-440.
6Seo S, Doi R, Machimoto T, et al. Contribution of ^18F- fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma[J]. J Hepatobiliary Pancreat Surg, 2008, 15(6):634-963.
7Farina JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms[J]. Ann Surg Oncol, 2008, 15(9): 2465-2471.
8Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of ^18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer [J]. Ann Surg, 2009, 250(6): 957-963.
9Nishiyama Y, Yamamoto Y, Yokoe K, et al . Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer[J]. Ann Nucl Med, 2005,19(6):491-497.
10Rose DM, Delbeke D, Beauchamp RD, et al. 18F-fluorodeoxyglucose-positron emission tomography in the mana- gement of patients with suspected pancreatic cancer [J]. Ann Surg, 1999, 229(5):729-738.
2Weller GER, Wong MKK, Modzelewski RA. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginineleucine[J]. Cancer Research, 2005, 65(2): 533-539.
3Yu MM,Wang RF, Yan P, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma [J]. J Label Compd Radiopharm, 2008, 51(11): 374-378.
4Patton JA, Townsend DW, Hutton BF. Hybrid imaging technology: from dreams and vision to clinical devices[J]. Semin Nucl Med, 2009, 39(4):247-263.
5Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning[J]. Nat Clin Pract Oncol, 2008, 5(3):160-170.
6Wehrl HF, Sauter AW, Judenhofer MS, et al. Combined PET/MR imaging-technology and applications [J]. Technol Cancer Res Treat, 2010, 9(1): 5-20.
7Liu M, Wang RF, Zhang CL, et al. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with ^99mTc-radiolabeled antisense probes in malignant tumors[J]. J Nucl Med, 2007, 48(12): 2028-2036.
3Lu X, Wang RF. A concise review of current radiopharma- ceuticals in tumor angiogenesis imaging [J]. Curr Pharm Des, 2012,18(8): 1032-1040.
4Pacini F,Castagna MG,Brilli L,et al. Thyroid cancer. ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2010,21 (Suppl 5) :v214-v219.
